Researchers at a Malawi–Liverpool–Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine in Blantyre, Malawi, studied the efficacy of a vaccine against infection with the Streptococcus pneumoniae bacteria, which causes invasive pneumococcal disease (IPD).
HIV–infected adults, particularly in sub–Saharan Africa, live in an increased risk of developing IPD. Experts tested the efficacy of Prevnar, a pneumococcal conjugate vaccine (PCV) developed by pharmaceutical company Wyeth, on almost five hundred predominantly HIV–infected adults who recovered from IPD after being admitted to the Queen Elizabeth Central Hospital in Blantyre.
Disclaimer: The news story on this page is the copyright of the cited publication. This has been reproduced here for visitors to review, comment on and discuss. This is in keeping with the principle of ‘Fair dealing’ or ‘Fair use’. Visitors may click on the publication name, in the news story, to visit the original article as it appears on the publication’s website.
Source :Times of India
